Industry
Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Loading...
Open
3.42
Mkt cap
690M
Volume
2.7M
High
3.45
P/E Ratio
-2.72
52-wk high
12.00
Low
3.03
Div yield
N/A
52-wk low
2.85
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:23 pm
Portfolio Pulse from Avi Kapoor
July 16, 2024 | 5:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 1:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 7:22 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 5:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:24 pm
Portfolio Pulse from Benzinga Insights
March 06, 2024 | 5:35 pm
Portfolio Pulse from Avi Kapoor
March 04, 2024 | 3:40 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 9:15 pm
Portfolio Pulse from Avi Kapoor
March 01, 2024 | 6:19 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.